Karin Wåhlander

2.0k total citations
36 papers, 1.5k citations indexed

About

Karin Wåhlander is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Karin Wåhlander has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 18 papers in Internal Medicine and 10 papers in Hematology. Recurrent topics in Karin Wåhlander's work include Atrial Fibrillation Management and Outcomes (20 papers), Venous Thromboembolism Diagnosis and Management (18 papers) and Blood Coagulation and Thrombosis Mechanisms (9 papers). Karin Wåhlander is often cited by papers focused on Atrial Fibrillation Management and Outcomes (20 papers), Venous Thromboembolism Diagnosis and Management (18 papers) and Blood Coagulation and Thrombosis Mechanisms (9 papers). Karin Wåhlander collaborates with scholars based in Sweden, United Kingdom and Denmark. Karin Wåhlander's co-authors include Henry Eriksson, Sam Schulman, Torbjörn Lundström, Per‐Olof Berggren, Ulf G. Eriksson, Patrik Rorsman, Carina Ämmälä, Krister Bokvist, David Gustafsson and Olof Larsson and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Karin Wåhlander

35 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Wåhlander Sweden	19	864	798	476	334	291	36	1.5k
J.J.J. van Giezen Sweden	20	1.3k 1.5×	542 0.7×	441 0.9×	369 1.1×	186 0.6×	41	1.9k
M. Urooj Zafar United States	22	754 0.9×	291 0.4×	442 0.9×	206 0.6×	240 0.8×	60	1.5k
Maddalena L. Zighetti Italy	18	404 0.5×	212 0.3×	243 0.5×	567 1.7×	173 0.6×	27	1.3k
Christian Stratz Germany	20	1.2k 1.3×	250 0.3×	632 1.3×	129 0.4×	172 0.6×	45	1.7k
Jean‐Louis David Belgium	19	481 0.6×	172 0.2×	282 0.6×	189 0.6×	153 0.5×	41	1.0k
Toshiro Shibano Japan	17	541 0.6×	274 0.3×	71 0.1×	304 0.9×	188 0.6×	54	1.0k
R De Caterina Italy	17	720 0.8×	238 0.3×	215 0.5×	70 0.2×	185 0.6×	54	1.3k
Rajnikant Patel United States	12	927 1.1×	172 0.2×	336 0.7×	57 0.2×	219 0.8×	14	1.2k
J.A. Jakubowski United States	17	410 0.5×	183 0.2×	230 0.5×	334 1.0×	178 0.6×	32	1.3k
N Islam United States	13	339 0.4×	105 0.1×	162 0.3×	326 1.0×	219 0.8×	18	1.3k

Countries citing papers authored by Karin Wåhlander

Since Specialization

Citations

This map shows the geographic impact of Karin Wåhlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Wåhlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Wåhlander more than expected).

Fields of papers citing papers by Karin Wåhlander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Wåhlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Wåhlander. The network helps show where Karin Wåhlander may publish in the future.

Co-authorship network of co-authors of Karin Wåhlander

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Wåhlander. A scholar is included among the top collaborators of Karin Wåhlander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Wåhlander. Karin Wåhlander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lindgren, A., Johanna Deinum, Göran Bergström, et al.. (2017). Fibrinolysis inhibitors in plaque stability: a morphological association of PAI‐1 and TAFI in advanced carotid plaque. Journal of Thrombosis and Haemostasis. 15(4). 758–769. 13 indexed citations

Svedlund, Sara, Juuso Blomster, Karin Wåhlander, et al.. (2016). Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects. Cardiovascular Diabetology. 15(1). 36–36. 23 indexed citations

Larsson, P., Niklas Bergh, Erik Ulfhammer, et al.. (2012). Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells. Journal of Thrombosis and Thrombolysis. 35(2). 185–192. 13 indexed citations

Tveit, Arnljot, et al.. (2010). Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thrombosis and Haemostasis. 103(3). 604–612. 47 indexed citations

Lip, Gregory Y.H., Lars Hvilsted Rasmussen, Sandra Olsson, et al.. (2010). Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thrombosis Research. 127(2). 91–99. 23 indexed citations

Svensson, Maria, et al.. (2010). Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837. European Journal of Clinical Pharmacology. 66(9). 903–910. 12 indexed citations

Lip, Gregory Y.H., Lars Hvilsted Rasmussen, Sandra Olsson, et al.. (2009). Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. European Heart Journal. 30(23). 2897–2907. 78 indexed citations

Larsson, P., Erik Ulfhammer, Lena Karlsson, et al.. (2008). Effects of IL-1β and IL-6 on tissue-type plasminogen activator expression in vascular endothelial cells. Thrombosis Research. 123(2). 342–351. 13 indexed citations

Nyström, Per, Ulf G. Eriksson, Troy C. Sarich, et al.. (2006). Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thrombosis and Haemostasis. 95(3). 447–453. 15 indexed citations

10.

Wåhlander, Karin, Henry Eriksson, Torbjörn Lundström, et al.. (2006). Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism. British Journal of Haematology. 133(1). 68–77. 13 indexed citations

11.

Cullberg, Marie, et al.. (2005). Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clinical Pharmacology & Therapeutics. 77(4). 279–290. 23 indexed citations

12.

Johansson, Susanne, et al.. (2005). No effect of encapsulation on the pharmacokinetics of warfarin. Biopharmaceutics & Drug Disposition. 26(3). 121–127. 2 indexed citations

13.

Schulman, Sam, Karin Wåhlander, & Torbjörn Lundström. (2004). Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor Ximelagatran. Journal of Vascular Surgery. 39(3). 695–695.

14.

Levi, Marcel, Troy C. Sarich, Ulf G. Eriksson, et al.. (2004). Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and Haemostasis. 91(6). 1090–1096. 73 indexed citations

15.

Eriksson, Henry, Karin Wåhlander, David Gustafsson, et al.. (2003). A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis. 1(1). 41–47. 128 indexed citations

16.

Sarich, Troy C., Julio Osende, Ulf G. Eriksson, et al.. (2003). Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. Journal of Thrombosis and Haemostasis. 1(5). 999–1004. 26 indexed citations

17.

Wolzt, Michael, et al.. (2003). Effects of the Oral Direct Thrombin Inhibitor Ximelagatran on P-Selectin Expression and Thrombin Generation in Atrial Fibrillation. Pathophysiology of Haemostasis and Thrombosis. 33(2). 68–74. 15 indexed citations

18.

Schulman, Sam, et al.. (2003). Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. New England Journal of Medicine. 349(18). 1713–1721. 330 indexed citations

19.

Wåhlander, Karin, Leif Lapidus, Carl‐Gustav Olsson, et al.. (2002). Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thrombosis Research. 107(3-4). 93–99. 59 indexed citations

20.

Rorsman, Patrik, Krister Bokvist, Carina Ämmälä, et al.. (1991). Activation by adrenaline of a low-conductance G protein-dependent K+ channel in mouse pancreatic B cells. Nature. 349(6304). 77–79. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact